Tag: Janssen Pharma

According to in-vitro investigations, Tremfya shows a distinct binding mechanism from risankizumab, according to Janssen Pharma.

Further findings from in vitro MODIF-Y tests from the Janssen Pharmaceutical Companies of Johnson & Johnson reinforce the idea that not all IL-23 inhibitors work the same way by showing that Tremfya (guselkumab) and risankizumab have different binding mechanisms. According…

Back to top

This will close in 0 seconds

Registration Form


This will close in 0 seconds